ATE311408T1 - Verbindendes protein - Google Patents

Verbindendes protein

Info

Publication number
ATE311408T1
ATE311408T1 AT02080494T AT02080494T ATE311408T1 AT E311408 T1 ATE311408 T1 AT E311408T1 AT 02080494 T AT02080494 T AT 02080494T AT 02080494 T AT02080494 T AT 02080494T AT E311408 T1 ATE311408 T1 AT E311408T1
Authority
AT
Austria
Prior art keywords
hcv
protein
unglycosylated
ubiquitous
hepatitis
Prior art date
Application number
AT02080494T
Other languages
English (en)
Inventor
Sergio Abrignani
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Application granted granted Critical
Publication of ATE311408T1 publication Critical patent/ATE311408T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
AT02080494T 1995-09-01 1996-08-30 Verbindendes protein ATE311408T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9517926.3A GB9517926D0 (en) 1995-09-01 1995-09-01 Binding protein

Publications (1)

Publication Number Publication Date
ATE311408T1 true ATE311408T1 (de) 2005-12-15

Family

ID=10780099

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96928648T ATE245166T1 (de) 1995-09-01 1996-08-30 Verwendung eines 24 kd proteins zur behandlung und diagnose einer hcv infektion
AT02080494T ATE311408T1 (de) 1995-09-01 1996-08-30 Verbindendes protein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96928648T ATE245166T1 (de) 1995-09-01 1996-08-30 Verwendung eines 24 kd proteins zur behandlung und diagnose einer hcv infektion

Country Status (14)

Country Link
US (4) US6737233B1 (de)
EP (2) EP0852586B1 (de)
JP (3) JP4223074B2 (de)
AT (2) ATE245166T1 (de)
AU (1) AU712540B2 (de)
CA (1) CA2227301C (de)
DE (2) DE69629121T2 (de)
DK (1) DK0852586T3 (de)
ES (1) ES2202459T3 (de)
GB (1) GB9517926D0 (de)
IL (1) IL123169A (de)
NZ (1) NZ316186A (de)
PT (1) PT852586E (de)
WO (1) WO1997009349A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416671D0 (en) * 1994-08-17 1994-10-12 Biocine Spa Assay
WO1999018198A1 (en) 1997-10-06 1999-04-15 Chiron S.P.A. Hepatitis c receptor protein cd81
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
CN102439444B (zh) 2009-01-29 2014-10-22 联邦科学技术研究组织 测量g蛋白偶联受体激活

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3886363T3 (de) 1987-11-18 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika
WO1990011089A1 (en) 1989-03-17 1990-10-04 Chiron Corporation Nanbv diagnostics and vaccines
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
EP0565172A1 (de) * 1992-04-10 1993-10-13 Quest International B.V. Klonierung und Expression von einer DNS, welche eine gereifte Form eines Polypeptides mit Sulfhydryl-Oxidase-Aktivität kodiert
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US6682909B2 (en) * 2000-09-13 2004-01-27 Hawaii Biotech, Inc. Immunogenic composition of hepatitis C and methods of use thereof

Also Published As

Publication number Publication date
IL123169A0 (en) 1998-09-24
AU6835196A (en) 1997-03-27
DE69635535T2 (de) 2006-08-17
GB9517926D0 (en) 1995-11-01
DE69629121T2 (de) 2004-05-27
DE69635535D1 (de) 2006-01-05
US20060166193A1 (en) 2006-07-27
ES2202459T3 (es) 2004-04-01
WO1997009349A1 (en) 1997-03-13
US20010027565A1 (en) 2001-10-04
ATE245166T1 (de) 2003-08-15
DK0852586T3 (da) 2003-11-03
AU712540B2 (en) 1999-11-11
DE69629121D1 (de) 2003-08-21
EP1321476A2 (de) 2003-06-25
JP2000500004A (ja) 2000-01-11
CA2227301C (en) 2013-08-27
EP1321476A3 (de) 2003-08-13
US7320875B2 (en) 2008-01-22
US7026130B2 (en) 2006-04-11
PT852586E (pt) 2003-12-31
EP0852586B1 (de) 2003-07-16
JP2008079613A (ja) 2008-04-10
EP1321476B1 (de) 2005-11-30
JP2007039462A (ja) 2007-02-15
EP0852586A1 (de) 1998-07-15
US6777538B2 (en) 2004-08-17
JP4223074B2 (ja) 2009-02-12
IL123169A (en) 2001-10-31
US20040180053A1 (en) 2004-09-16
CA2227301A1 (en) 1997-03-13
US6737233B1 (en) 2004-05-18
NZ316186A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
DK0539530T3 (da) Rensningsstyret kloning af peptider
DE3583293D1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
ATE206717T1 (de) Hcv-spezifische peptide, mittel dazu und ihre verwendung
FI935808A0 (fi) Hepatit-C-virus (HCV) polypeptider
DE69030124D1 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus
ID30380A (id) Penghambatan infeksi virus menggunakan protein pengikat antigen bervalensi tunggal
IT1278077B1 (it) Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
LU91394I2 (fr) "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix
DE68903165D1 (de) Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein.
DK0554389T3 (da) Molekylære kloner af HIV-1 og anvendelse deraf
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
DE69635535D1 (de) Verbindendes Protein
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
DE60034243D1 (de) Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DE3852762D1 (de) Expression der immunoaktiven proteine von menschlichem b-lymphotropikvirus.
IT1270941B (it) Peptidi di hcv e loro usi.
TH4070EX (th) ลำดับ dna ที่มีรหัสของเซอร์เฟสแอนติเจนโปรตีน p31 ที่ดัดแปลงของไวรัสเฮพพาทิทิส บี
TH46562A3 (th) สายพันธุ์ไวรัสมิวแทนท์ฃเฮพาไททิส บี ของคนและการใช้งานของมัน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1321476

Country of ref document: EP

EEFA Change of the company name